Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015


  • Products Id :- GDHC2682CTIDB
  • |
  • Pages: 93
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015

GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015" provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each

Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons To Buy

Understand the dynamics of a particular indication in a condensed manner

Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

Obtain discontinued trial listing for trials across the globe

Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Non-Alcoholic Steatohepatitis 7

Report Guidance 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 16

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 19

Clinical Trials by Phase in E7 Countries 20

Clinical Trials in E7 Countries by Trial Status 21

Clinical Trials by Phase 22

In Progress Trials by Phase 23

Clinical Trials by Trial Status 24

Clinical Trials by End Point Status 25

Unaccomplished Trials of Non-Alcoholic Steatohepatitis 26

Subjects Recruited Over a Period of Time 28

Clinical Trials by Sponsor Type 29

Prominent Sponsors 30

Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials 31

Prominent Drugs 32

Latest Clinical Trials News on Non-Alcoholic Steatohepatitis 33

May 04, 2015: Islet Sciences Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH 33

Apr 23, 2015: Diabetes drug shows promise in the treatment of non-alcoholic steatohepatitis 33

Apr 23, 2015: Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients 34

Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH 35

Apr 21, 2015: Nimbus Therapeutics Announces Initiation of Clinical Studies for ACC Inhibitor 36

Apr 21, 2015: Upcoming AACR and EASL poster presentations support Nimbus' novel, liver-directed approach to allosteric ACC inhibition across liver disease spectrum, including NASH and HCC 36

Apr 20, 2015: NGM Biopharmaceuticals to Present New Data on NGM282 at the European Association for the Study of the Liver International Liver Congress 2015 37

Apr 08, 2015: Tobira Therapeutics Highlights Presentations at The International Liver Congress 2015 37

Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 38

Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 38

Mar 26, 2015: Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan 39

Mar 20, 2015: Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH 40

Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease 41

Mar 12, 2015: Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA 41

Mar 09, 2015: Islet Sciences COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH) 42

Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States 42

Feb 25, 2015: MediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at the AASLD and Industry Colloquium: Novel Targets and Therapies in Liver Disease in Durham, North Carolina 43

Feb 24, 2015: Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02 43

Clinical Trial Profiles 45

Clinical Trial Overview of Top Companies 45

Genextra S.p.a. 45

Clinical Trial Overview of Genextra S.p.a. 45

Genfit SA 46

Clinical Trial Overview of Genfit SA 46

Cempra, Inc. 47

Clinical Trial Overview of Cempra, Inc. 47

Raptor Pharmaceuticals Corp. 48

Clinical Trial Overview of Raptor Pharmaceuticals Corp. 48

Nimbus Therapeutics, LLC 49

Clinical Trial Overview of Nimbus Therapeutics, LLC 49

Immuron Limited 50

Clinical Trial Overview of Immuron Limited 50

Gilead Sciences, Inc. 51

Clinical Trial Overview of Gilead Sciences, Inc. 51

Galmed International Ltd. 52

Clinical Trial Overview of Galmed International Ltd. 52

Galectin Therapeutics, Inc. 53

Clinical Trial Overview of Galectin Therapeutics, Inc. 53

DURECT Corporation 54

Clinical Trial Overview of DURECT Corporation 54

Clinical Trial Overview of Top Institutes / Government 55

The National Institute of Diabetes and Digestive and Kidney Diseases 55

Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 55

Tehran University of Medical Sciences 56

Clinical Trial Overview of Tehran University of Medical Sciences 56

University of California, San Diego 57

Clinical Trial Overview of University of California, San Diego 57

National Nutrition and Food Technology Research Institute 58

Clinical Trial Overview of National Nutrition and Food Technology Research Institute 58

Yokohama City University 59

Clinical Trial Overview of Yokohama City University 59

Bambino Gesu Hospital and Research Institute 60

Clinical Trial Overview of Bambino Gesu Hospital and Research Institute 60

Ghent University Hospital 61

Clinical Trial Overview of Ghent University Hospital 61

Gunma Liver Study Group 62

Clinical Trial Overview of Gunma Liver Study Group 62

Hadassah Medical Organization 63

Clinical Trial Overview of Hadassah Medical Organization 63

Hiroshima University Hospital 64

Clinical Trial Overview of Hiroshima University Hospital 64

Five Key Clinical Profiles 65

Appendix 91

Abbreviations 91

Definitions 91

Research Methodology 92

Secondary Research 92

About GlobalData 93

Contact Us 93

Disclaimer 93

Source 93

List of Figures

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region (%), 2015* 8

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 11

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 12

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 13

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 14

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 15

Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 16

Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 19

Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20

Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28

Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 29

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32

GlobalData Methodology 92

List of Tables

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region, 2015* 8

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 11

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 12

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries, 2015* 13

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 14

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 15

Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 16

Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 19

Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20

Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase, 2015* 22

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23

Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25

Non-Alcoholic Steatohepatitis Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26

Non-Alcoholic Steatohepatitis Therapeutics, Global, Terminated Clinical Trials, 2015* 27

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28

Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 29

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Genextra S.p.a., 2015* 45

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Genfit SA, 2015* 46

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cempra, Inc., 2015* 47

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Raptor Pharmaceuticals Corp., 2015* 48

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nimbus Therapeutics, LLC, 2015* 49

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Immuron Limited, 2015* 50

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2015* 51

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Galmed International Ltd., 2015* 52

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Galectin Therapeutics, Inc., 2015* 53

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by DURECT Corporation, 2015* 54

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2015* 55

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2015* 56

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2015* 57

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Nutrition and Food Technology Research Institute, 2015* 58

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yokohama City University, 2015* 59

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bambino Gesu Hospital and Research Institute, 2015* 60

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Ghent University Hospital, 2015* 61

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Gunma Liver Study Group, 2015* 62

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hadassah Medical Organization, 2015* 63

Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hiroshima University Hospital, 2015* 64

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Genextra S.p.a.

Genfit SA

Cempra, Inc.

Raptor Pharmaceuticals Corp.

Nimbus Therapeutics, LLC

Immuron Limited

Gilead Sciences, Inc.

Galmed International Ltd.

Galectin Therapeutics, Inc.

DURECT Corporation

Non-Alcoholic Steatohepatitis Clinical Trials, Trial Designs, Subjects Recruited, Unaccomplished Trials of Non-Alcoholic Steatohepatitis , Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas, M.D. Andersons, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, National Cancer Center, University of Pennsylvania.

select a license

Single User License
USD 2500 INR 179700
Site License
USD 5000 INR 359400
Corporate User License
USD 7500 INR 539100

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com